Calcitonin drug-oligomer conjugates, and uses thereof

• US 8,030,269 B2
• Filed: 10/27/2009
• Issued: 10/04/2011
• Est. Priority Date: 06/04/2001
• Status: Expired due to Fees

• Current Assignee: Biocon Limited (Biocon Incorporated)
• Original Assignee: Biocon Limited (Biocon Incorporated)
• Inventors: Radhakrishnan, Balasingam, Ekwuribe, Nnochiri N.
• Primary Examiner(s): Tate; Christopher R.
• Assistant Examiner(s): Teller; Roy
• Application Number:
  US12/606,455
• Publication Number:
  US 20100105624A1
• Time in Patent Office: 707 Days
• Field of Search: None
• US Class Current: 514/1.1
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: C07K 14/585 Calcitonins

Abstract

Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.

Claims

1. A pharmaceutical composition comprising a monodispersed calcitonin-oligomer conjugate comprising salmon calcitonin coupled to two oligomer subunits, wherein each oligomer consists of the structure of Formula I:

2. A method of treating a bone disorder in a subject in need of such treatment, said method comprising:

administering an effective amount of a monodispersed calcitonin-oligomer conjugate comprising salmon calcitonin coupled to two oligomer subunits, wherein each oligomer consists of the structure of Formula I;

3. The method according to claim 2, wherein administration is oral.